Cellyan Biotechnology Co Ltd（HKPD）の株式分析HKPDCellyan Biotechnology Co Ltd

Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.

Given the current price of HKPD at $0.35 and a year-to-date change of -56.97%, it is not advisable to buy this asset right now. The RSI is at 33.28, indicating that the stock is oversold, but the negative momentum and declining performance over the past year (down 76.06%) raise serious concerns. Furthermore, the forward P/E ratio is at 0, suggesting a lack of expected earnings growth, and the gross margin has dropped to 10.32% in the latest quarter, which is significantly low. The primary risk is the recent compliance warning from Nasdaq, which could further depress the stock price if the company fails to meet the minimum bid price requirement.